Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck(Dana-Farber Cancer Institute), Barbara Weber(University of St.Gallen), Laura van ‘t Veer, Theresa Wagner(Fox Chase Cancer Center), Katrina Armstrong(Columbia University), Gail E. Tomlinson(Urology San Antonio), Olufunmilayo I. Olopade(University of Chicago), Susan L. Neuhausen(City of Hope), Susan M. Domchek(University City Science Center), Andrea Eisen(Sunnybrook Health Science Centre), Claudine Isaacs(Georgetown University), D. Gareth Evans(Manchester Academic Health Science Centre), Steven A. Narod(Women's College Hospital), Judy E. Garber(Fox Chase Cancer Center), Mary B. Daly(Fox Chase Cancer Center), Ellen Matloff(Fox Chase Cancer Center), Tara M. Friebel(Fox Chase Cancer Center), Henry T. Lynch(Creighton University), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust)
Cited by 406
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer
|Science|1994|1.8k